Back to Search
Start Over
Efficacy and safety of self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (MND-2119) versus highly purified eicosapentaenoic acid ethyl ester in patients with hypertriglyceridemia: Results from a 12-week randomized,...
- Source :
- Journal of Clinical Lipidology; Sep2022, Vol. 16 Issue 5, p704-714, 11p
- Publication Year :
- 2022
-
Abstract
- • MND-2119 is a self-emulsifying eicosapentaenoic acid ethyl ester. • MND-2119 was tested in hypertriglyceridemia patients. • MND-2119 2 g/day was non-inferior to Epadel 1.8 g/day in lowering TG levels. • MND-2119 4 g/day was superior to MND-2119 2 g/day in lowering TG levels. • MND-2119 appeared safe and well tolerated. In Japan, eicosapentaenoic acid ethyl ester (EPA-E) is administered twice-daily or three-times-daily for dyslipidemia. We have developed MND-2119, a novel self-emulsifying formulation of highly purified EPA-E, which can be administered once-daily. The objective of this study was to assess non-inferiority in the efficacy of MND-2119 in patients with hypertriglyceridemia compared with highly purified EPA-E. In this multicenter, 12-week, double-blind study, patients with high triglyceride (TG levels between ≥ 150 and < 500 mg/dL) undergoing lifestyle modification were randomized to MND-2119 2 g/day (n=145), MND-2119 4 g/day (n=145), EPA-E 1.8 g/day (n=145) or EPA-E 2.7 g/day (n=145). The primary endpoint was percentage change in TG levels from baseline to end of treatment. MND-2119 2, 4 g/day and EPA-E 1.8, 2.7 g/day reduced TG levels from baseline by −10.09%, −15.51%, −9.30%, and −8.80%, respectively. The TG reduction rate of MND-2119 2 g/day was non-inferior to that of EPA-E 1.8 g/day (LS mean difference: -0.42, 95%CI: -5.76 to 4.91). Moreover, the TG reduction rate of MND-2119 4 g/day was superior to that of MND-2119 2 g/day (LS mean difference: -5.74, 95%CI: -10.59 to -0.89). There were no remarkable safety differences between MND-2119 2 g/day and EPA-E 1.8 g/day and between MND-2119 4 g/day and EPA-E 2.7 g/day. Non-inferiority of MND-2119 2 g/day to EPA-E 1.8 g/day for efficacy, and superiority of MND-2119 4 g/day over MND-2119 2 g/day for efficacy were verified. MND-2119 was safe and well tolerated. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 19332874
- Volume :
- 16
- Issue :
- 5
- Database :
- Supplemental Index
- Journal :
- Journal of Clinical Lipidology
- Publication Type :
- Academic Journal
- Accession number :
- 160168113
- Full Text :
- https://doi.org/10.1016/j.jacl.2022.06.007